NEUMORA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
NEUMORA THERAPEUTICS, INC. (NMRA) had Debt Securities, Available-for-sale, Amortized Cost of $73.45 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-03-30
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $73.45M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $151.85M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $198.84M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $290.66M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-09-30 | $73.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $151.85M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $198.84M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $290.66M 10-K · filed 2026-03-30 |
| 2024-09-30 | $332.28M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $305.26M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $383.06M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $452.12M 10-K · filed 2025-03-03 |
| 2023-09-30 | $497.04M 10-Q · filed 2023-11-01 |
| 2022-12-31 | $338.58M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |